Clinical trial · Observational
Cohort of Patients With Chronic Myelomonocytic Leukemia
NCT07512882CI-TRIAL-00111977MYELOMONO-3recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
A prospective, non-interventional study involving the collection of biological samples with associated anonymised data. Biological samples will be collected at the time of diagnosis and/or as the disease progresses, with or without treatment, always in conjunction with tests scheduled as part of routine care or within the context of a clinical trial.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia | Leukemia | ONTOLOGY_EXACT | 0.90 |
| Myelomonocytic Leukemia, Chronic | Chronic Myelomonocytic Leukemia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Sampling | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Cohort of patients with chronic myelomonocytic leukemia
- interventionNames
- Biological: Sampling
Primary outcomes (1)
- measure
- Understanding the pathophysiology of chronic myelomonocytic leukaemia
- timeFrame
- through study completion, an average of 15 years
- description
- optimise diagnosis, improve prognostic stratification, identify new treatment options and assess patients' response to proposed treatments through the analysis of blood or bone marrow samples collected as part of routine care or clinical trials
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Adults aged 18 years and over * Blood monocytosis ≥ 0.5 × 10⁹/L and ≥ 10% of total white blood cells or * Confirmed diagnosis of chronic myelomonocytic leukemia * Regardless of stage (chronic or transformed), and whether or not currently being treated * Signed informed consent Exclusion Criteria: * Active, uncontrolled infection (particularly hepatitis B, hepatitis C, HIV) * Refusal informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.